Documents

Record Q1 revenue and robust growth in chronic therapies, with margin guidance maintained.

Strong FY26 growth, major launches, and FY27 guidance for higher margins and U.S. expansion.

Flat revenue, margin pressure, and U.S. supply issues offset by robust India growth and new launches.

Quarterly revenue hit an all-time high, with strong growth and revised margin guidance.

Q1 FY26 delivered steady growth, strong margins, and a robust pipeline to fuel future expansion.

Q4 revenue up 9% YoY, EBITDA margin beats guidance, outlook steady despite margin pressures.

Record revenue and margins achieved; U.S. launches and growth to accelerate in FY26.

Record EBITDA margin and strong growth in India and Africa, despite US supply headwinds.

Revenue up 7% YoY, EBITDA margin at 25.6%, with strong growth in key markets.